🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hormone Receptor Positive HER-2 Negative Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients NCT06388122n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases NCT04923542Phase 1, Phase 22 sites📍 Tampa📍 Columbus H. Lee Moffitt Cancer Center and Research Institute · Tests: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer NCT07112053Phase 21 site📍 Seattle University of Washington · Tests: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4… SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site📍 Orange University of California, Irvine · Tests: Fulvestrant, Anastrozole, Abemaciclib PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Tirzepatide Weight Loss for MRD+ Early Breast Cancer NCT06517212Phase 21 site📍 Dallas Baylor Research Institute · Tests: Tirzepatide Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site📍 La Jolla University of California, San Diego · Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physicia… ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management NCT05362760Phase 454 sites📍 Aalen📍 Amberg📍 Aschaffenburg Prof. Wolfgang Janni · Tests: Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Dalpiciclib, Endocrine therapy Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study NCT07647016Phase 21 site📍 Shanghai Fudan University · Tests: Trastuzumab Deruxtecan and ivonescimab Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer NCT06106477NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Intermittent Fasting Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer NCT07180056n/a1 site📍 Shanghai Wenjin Yin · Tests: CDK4/6 inhibitor First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors NCT07258108Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Lucanisatuzumab plus tagolimumab Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients NCT05452213Phase 452 sites📍 Erlangen📍 Mainz📍 Bottrop Institut fuer Frauengesundheit · Tests: Ribociclib Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites📍 Boston📍 St Louis National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) NCT07190443Phase 31 site📍 Koto-ku Japanese Foundation for Cancer Research · Tests: Endocrine therapy + Abemaciclib, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy